These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26840041)

  • 1. Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature.
    Birrer N; Chinchilla C; Del Carmen M; Dizon DS
    Am J Clin Oncol; 2018 Mar; 41(3):313-315. PubMed ID: 26840041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
    Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
    Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    Loizzi V; Dellino M; Cerbone M; Arezzo F; Cazzato G; Damiani GR; Pinto V; Silvestris E; Kardhashi A; Cicinelli E; Cascardi E; Cormio G
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
    Guidozzi F
    Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to hormone therapy following prophylactic bilateral salpingo-oophorectomy in BRCA1/2 mutation carriers.
    DiSilvestro JB; Haddad J; Robison K; Beffa L; Laprise J; Scalia-Wilbur J; Raker C; Clark M; Lokich E; Hofstatter E; Dalela D; Brown A; Bradford L; Toland M; Stuckey A
    Menopause; 2023 Jul; 30(7):732-737. PubMed ID: 37192837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes following risk reducing surgery in BRCA carriers.
    Gaba F; Manchanda R
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():46-65. PubMed ID: 32192936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
    Perri T; Farhadian Y; Friedman E; Korach J
    Menopause; 2020 Jan; 27(1):82-87. PubMed ID: 31688415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
    Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
    Kotsopoulos J; Gronwald J; Lubinski J; McCuaig J; Lynch HT; Neuhausen SL; Foulkes WD; Weitzel JN; Senter L; Tung N; Eng C; Karlan B; Sun P; Narod SA;
    Menopause; 2020 Feb; 27(2):156-161. PubMed ID: 31644510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
    Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
    JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
    Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
    Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
    Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
    Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy.
    Teixeira N; Mourits MJ; Oosterwijk JC; Fakkert IE; Absalom AR; Bakker SJL; van der Meer P; de Bock GH
    Fam Cancer; 2019 Jan; 18(1):19-27. PubMed ID: 29881922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    Huber D; Seitz S; Kast K; Emons G; Ortmann O
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2035-2045. PubMed ID: 33885953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
    Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
    BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
    Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
    BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone therapy in oophorectomized BRCA1/2 mutation carriers.
    Marchetti C; Iadarola R; Palaia I; di Donato V; Perniola G; Muzii L; Panici PB
    Menopause; 2014 Jul; 21(7):763-8. PubMed ID: 24253485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
    Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient reported experiences following laparoscopic prophylactic bilateral salpingo-oophorectomy or salpingectomy in an ambulatory care hospital.
    Trister R; Jacobson M; Nguyen P; Sobel M; Allen L; Narod SA; Kotsopoulos J
    Fam Cancer; 2021 Apr; 20(2):103-110. PubMed ID: 32964297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.